Stiftung Katholisches Marienhospital Aachen
- Address
- Zeise 4, 52066 Aachen, Germany
Stiftung Katholisches Marienhospital Aachen - Breast Cancer Research Center
Stiftung Katholisches Marienhospital Aachen is a specialized clinical research institution focused on advancing personalized treatment strategies for breast cancer. The center demonstrates particular expertise in adjuvant therapy optimization for hormone receptor-positive, HER2-negative early breast cancer, utilizing dynamic marker-adjusted approaches to tailor treatments to individual patient risk profiles.
- Personalized endocrine therapy combined with CDK4/6 inhibitors (abemaciclib, ribociclib) for HR+/HER2- early breast cancer
- Comparative effectiveness research evaluating targeted therapy versus chemotherapy in intermediate to high-risk patient populations
- Long-term survival outcomes including invasive disease-free survival (iDFS) and distant disease-free survival (dDFS)
The center's research portfolio emphasizes marker-adjusted personalized therapy through the ADAPT trial series, investigating whether CDK4/6 inhibitor combinations can improve outcomes compared to standard chemotherapy or endocrine therapy alone. Their work aims to identify optimal treatment strategies that maximize invasive disease-free survival while potentially sparing patients from unnecessary chemotherapy through precision medicine approaches in early-stage breast cancer management.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
No sponsors linked to active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Stiftung Katholisches Marienhospital Aachen
lock Showing 1 of 2 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Adjuvant Dynamic Marker-Adjusted Personalized Therapy: Ribociclib Plus Endocrine Therapy Versus Chemotherapy in HR+/HER2- Early Breast Cancer | WSG Westdeutsche Studiengruppe GmbH | Phase III | Not Recruiting | Jul 2019 | — |
IMP list
lock Showing 1 of 2 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Abemaciclib | 1 | Unknown | 2020-07-23 | 2020-07-23 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.